-

Posts Tagged ‘antiretrovirals’

WHO HIV Treatment Guidelines Updated

Paul Sax • November 30th, 2009

Categories: Health Care, HIV, Patient Care, Policy

(4 votes, average: 3.25 out of 5)

This just in: WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms. Which makes eminent sense, of course.  Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing [...]

March (Guideline) Madness …

Paul Sax • March 25th, 2009

Categories: Health Care, HIV, Infectious Diseases, Misc, Patient Care

(No Ratings Yet)

A couple of interesting ID guidelines out this week.  For those of you too busy with basketball, here are the relevant links: Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities. Identified in 24 states and now found “routinely” in New York and New Jersey, these carbapenem-resistant Enterobacteriaceae (“CPE” is [...]

Unintended Consequences of ART “Rollout”

Paul Sax • December 10th, 2008

Categories: Health Care, HIV, Infectious Diseases, Misc, Patient Care, Policy

(No Ratings Yet)

According to this BBC article, teenagers in South Africa are grinding up antiretrovirals and then smoking them for their “hallucinogenic and relaxing effect”.  (Apologies for the pun on the title.) It’s impossible to tell with a report like this how widespread the practice is, but it’s potentially worrisome.  And no mention in the article which antivirals are [...]

“Salvage” Rx for HIV: Macro Good News, Micro Bad News

Paul Sax • November 22nd, 2008

Categories: HIV, Infectious Diseases, Patient Care

(No Ratings Yet)

I’ve written before how the number of treatment experienced patients who have no options for successful therapy has dwindled to a tiny — but unfortunate — few.  Darunavir, maraviroc, raltegravir, and etravirine (in order of FDA approval) are that good. Two presentations at recent scientific meetings confirmed the staggering efficacy of these newer drugs. Notably, [...]

Antiretrovirals in the Pipeline: And Then There Were … None?

Paul Sax • April 23rd, 2008

Categories: Health Care, HIV, Infectious Diseases, Patient Care

(No Ratings Yet)

The flurry of drug approvals that began in 2005 with tipranavir – followed rapidly by darunavir, maraviroc, raltegravir, and most recently etravirine – has been nothing short of astounding. Every experienced HIV clinician now has many patients who are on successful (read: suppressive) treatment for the first time ever. The Vancouver HIV program – wonderfully called [...]